Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer
Overview
GnRH analogs are globally used for assisted reproduction in infertile patients. To date, in healthy female volunteers the pharmacokinetic and pharmacodynamic profiles of cetrorelix when administered in a single dose have been investigated in studies conducted using doses of 1, 3 and 5 mg. Studies performed in premenopausal female volunteers confirmed that cetrorelix rapidly suppresses luteinizing hormone (LH) and estradiol and shows dose-dependent prolongation of the duration of LH suppression. However, there have been few reports of studies of the relationship between the cetrorelix dosage and its effect on LH surge. In the present study, we investigated the effect of cetrorelix on LH surge when this drug was administered in single doses of 1, 2 and 3 mg.
Full Title of Study: “Clinical Pharmacological Study of NS75A for Healthy Adult Women”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Single (Participant)
Detailed Description
To evaluate that effect on LH surge, we investigated the efficacy of cetrorelix in delaying the start of the LH surge in comparison with the control menstrual cycle when saline was administered, and also examined the mode of disappearance of pulsatile LH secretion during the cetrorelix administration menstrual cycle.
Interventions
- Drug: Cetrorelix
- 1, 2 or 3mg, subcutaneouly dosed with single dose
Arms, Groups and Cohorts
- Experimental: Cetrorelix 1 mg
- Experimental: Cetrorelix 2 mg
- Experimental: Cetrorelix 3 mg
Clinical Trial Outcome Measures
Primary Measures
- Day of the LH surge
- Time Frame: Saline administration menstrual cycle, cetrorelix administration menstrual cycle
Secondary Measures
- Serum LH concentrations
- Time Frame: Saline administration menstrual cycle, cetrorelix administration menstrual cycle
Participating in This Clinical Trial
Inclusion Criteria
- a BMI of 18 years old and <18 and 25 years old and >25 – menstrual cycles was within the range of 25~31 days Exclusion Criteria:
- use of a drug (e.g., oral contraceptives, drugs for treatment of hyperprolactinemia, GnRH agonists, sex steroid hormones, psychoactive drugs, etc.) – serious disease of the endocrine system, liver, kidney, heart, lung, digestive system, etc. – a generalized drug allergy
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: 25 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Collaborator
- Shionogi
- Provider of Information About this Clinical Study
- Nippon Kayaku Co., Ltd.,
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.